

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of preventing the formation of inhibitory antibodies to Factor IX delivered to a mammal by way of an adeno-associated viral vector, wherein said mammal has a ~~genetic defect~~ large gene deletion in a gene encoding Factor IX which can result in generation of inhibitory antibodies to Factor IX upon administration of exogenous Factor IX, said method comprising intravenously or intraperitoneally administering to said mammal cyclophosphamide prior to or simultaneously with said adeno-associated viral vector delivery before formation of said inhibitory antibodies, the delivered Factor IX being from the same species as said mammal.

2. (Previously Presented) The method of claim 1, wherein said mammal and gene are human.

3-23. (Cancelled)

24. (Currently amended) The method of claim 1, wherein said mammal has no detectable endogenous expression of ~~the delivered Factor IX~~ due to the presence of said large gene deletion in said gene encoding Factor IX.

25-27. (Cancelled)

28. (Previously Presented) The method of claim 1, wherein said cyclophosphamide is administered concomitantly with said adeno-associated viral vector.

29-42. (Cancelled)

43. (Previously Presented) The method of claim 1, wherein Factor IX production in said mammal induces formation of said inhibitory antibodies which are optionally determined by Bethesda titers.

44. (Currently amended) The method of claim 1, wherein said mammal has hemophilia B and said AAV vector is administered intramuscularly.